Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment
|
|
- Alicia Wilkins
- 8 years ago
- Views:
Transcription
1 International Journal of Neuropsychopharmacology (2006), 9, Copyright f 2005 CINP doi: /s Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment ARTICLE Matthew N. Hill, Jane C. Sun, Maric T. L. Tse and Boris B. Gorzalka Department of Psychology, University of British Columbia, Vancouver, BC, Canada Abstract This study examined the effects of long-term cannabinoid administration on the responsivity of 5-HT 1A and 5-HT 2A receptors, which have been implicated in depression. Animals received 12 d administration of the potent cannabinoid receptor agonist HU-210 (100 mg/kg), following which they were monitored on their behavioural, physiological and hormonal responses to a single challenge of a 5-HT 1A and 5-HT 2A receptor agonist, 8-OH-DPAT (0.3 mg/kg) and DOI (1 mg/kg) respectively. treatment lead to a significant enhancement of DOI-induced wet-dog shakes, but a reduction of DOI-induced back muscle contractions. DOI-induced corticosterone release was unaffected by HU-210 treatment. The hyperthermic response to DOI appeared to be potentiated by long-term HU-210 treatment, as 50% of these subjects died from an apparent serotonin syndrome with core temperatures exceeding 43 xc. The 8-OH- DPAT-induced hypothermic response and elevation of corticosterone were both significantly attenuated by long- term HU-210 treatment. These data imply that chronic cannabinoid treatment may up-regulate 5-HT 2A receptor activity while concurrently down-regulating 5-HT 1A receptor activity, a finding similar to that sometimes observed in depression. This may partially explain the association between excessive cannabis consumption and the induction of affective disease. Received 11 February 2005; Reviewed 19 March 2005; Revised 11 April 2005; Accepted 13 April 2005; First published online 21 June 2005 Key words: Cannabinoid, corticosterone, depression, hypothermia, 5-HT 1A, 5-HT 2A. Introduction The serotonin (5-HT) system is a diverse and intricate system composed of at least 14 identified receptor subtypes (Barnes and Sharp, 1999). Serotonergic nerve fibres originate in the raphe nuclei of the hindbrain and project diffusely throughout the brain, innervating almost every major brain structure (Abrams et al., 2004). One interesting aspect of the 5-HT system is the reciprocal interactions many of its receptors have with one another. For example, 5-HT 1A and 5-HT 2A receptors appear to exhibit opposing roles (Araneda and Andrade, 1991; Ashby et al., 1994; Darmani et al., 1990). Specifically, activation of 5-HT 1A receptors typically results in cellular hyperpolarization and inhibition of cell firing, whereas activation of 5-HT 2A receptors induces cellular depolarization and increased Address for correspondence : Dr B. B. Gorzalka, Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver, BC, Canada V6T 1Z4. Tel. : Fax : bgorzalka@psych.ubc.ca cell firing (Araneda and Andrade, 1991; Bobker, 1994; Craven et al., 2001). Concomitant activation of one of these receptors results in a functional inhibition of the other, suggesting that the net effect of serotonergic activity is delicately regulated by the balance of these two receptors. This is exemplified by the demonstration that the ability of 5-HT 1A receptor agonists to suppress the firing rate of spontaneously active cortical cells is potentiated by the concurrent administration of 5-HT 2A receptor antagonists, and the ability of 5-HT 2A receptor ligands to enhance glutamate-induced cell firing is counteracted by administration of 5-HT 1A receptor agonists (Ashby et al., 1994). This reciprocal regulation of 5-HT 1A and 5-HT 2A receptors is also seen in behavioural research. Administration of ligands for the 5-HT 1A receptor attenuate the expression of 5-HT 2A receptor-mediated stereotypies such as wet-dog shakes, and administration of antagonists at the 5-HT 1A receptor potentiate 5-HT 2A receptor-mediated wet-dog shakes (Darmani et al., 1990, 1991; Willins and Meltzer, 1997). Furthermore, administration of 5-HT 2A receptor antagonists
2 278 M. N. Hill et al. enhances the behavioural responses to administration of a 5-HT 1A agonist (Backus et al., 1990). Additionally, these two receptors appear to elicit opposing behavioural responses, with 5-HT 1A receptor activation inducing hyperphagia, increased male sexual behaviour, anxiolysis and hypothermia whereas activation of the 5-HT 2A receptor induces hyperthermia, reduced male sexual behaviour, anxiogenesis and hypophagia (Abdel-Fattah et al., 1995; Eison and Eison, 1994; Gorzalka et al., 1990; Simansky, 1996). This suggests a dynamic relationship exists between the 5-HT 1A and 5-HT 2A receptors that requires an optimal level of activity at both receptors, and that alterations in one receptor subtype will inevitably affect the other. The endocannabinoid system is a neuromodulatory system in the brain, which shares a high level of overlap with the serotonergic system in terms of the physiological processes it regulates. For example, both the serotonergic and endocannabinoid systems regulate body temperature, feeding behaviour, sleep and arousal and emotional processes (Abdel-Fattah et al., 1995; Chaperon and Thiebot, 1999; Eison and Eison, 1994; Santucci et al., 1996; Simansky, 1996). Despite the extent of the similarity between these two systems, relatively little is known about their functional interactions. In-vitro and in-vivo work has suggested that cannabinoids may influence 5-HT release. Specifically, cannabinoid receptor (CB 1 ) agonists suppress electrically and Ca 2+ -stimulated 5-HT release from cortical slices (Nakazi et al., 2000) and administration of CB 1 receptor antagonists stimulates 5-HT release into the medial prefrontal cortex (Darmani et al., 2003; Tzavara et al., 2003). In the hippocampus, the psychoactive constituent of cannabis, delta9 tetrahydrocannabinol (THC) has been shown to inhibit 5-HT release (Egashira et al., 2002). This suppression of serotonergic neurotransmission by cannabinoids is believed to be involved in the mnemonic effects of THC as treatment with the 5-HT precursor, 5-hydroxytryptophan (5-HTP), or the 5-HT reuptake inhibitor clomipramine reversed this deficit (Egashira et al., 2002). Thus, while cannabinoids may regulate serotonergic release and transmission, very little is known about the direct relationship between cannabinoids and specific 5-HT receptor subtypes. Biochemical work has suggested that endocannabinoids may enhance 5-HT 1A receptor-mediated responses but attenuate 5- HT 2A receptor-mediated responses (Boger et al., 1998), a finding partially supported by behavioural studies demonstrating that acutely, cannabinoid administration can reduce 5-HT 2A receptor-mediated behavioural responses (Cheer et al., 1999; Darmani, 2001; Gorzalka et al., 2005). The effects of acute administration of cannabinoid ligands on 5-HT 1A receptor-mediated behavioural responses remain to be determined. To date there have been no studies examining the effect of chronic cannabinoid administration on the balance of 5-HT receptors. Using behavioural, physiological and hormonal measures of both 5-HT 1A and 5-HT 2A receptor responses, the present study examined the effect of chronic administration of the cannabinoid CB 1 receptor agonist HU-210 on the responsiveness of 5-HT 1A and 5-HT 2A receptors. Methods Subjects and treatment Seventy-day-old male Long Evans rats (300 g) housed in groups of three in triple-mesh wire cages were used in this study. Colony rooms were maintained at 21 xc, and on a reverse 12 h light/dark cycle, with lights off at 09:00 hours. All rats were given ad libitum access to Purina rat chow and tap water. All subjects were randomly divided into two groups: (1) 100 mg/kg HU-210 (Tocris-Cookson, Bristol, UK); or (2) vehicle (1:1: 18; Tween-80: dimethyl sulphoxide: 0.9% saline). All injections were performed intraperitoneally using 26- gauge 1 2-inch needles, during the last third of the dark cycle. All subjects received either HU-210 or vehicle injections for 12 consecutive days. Twenty-four hours following the final injection, both groups were then divided into three subgroups: (1) vehicle (0.9% saline); (2) 0.3 mg/kg 8-hydroxy-2-(N,N-dipropylamino)tetralin (8-OH-DPAT; a 5-HT 1A receptor agonist; Sigma-Aldrich, Oakville, ON, Canada); (3) 1 mg/kg ((1-)2,5-dimethoxy-4-iodophenyl)-2- aminopropane (DOI; a 5-HT 2A/2C receptor agonist; Sigma-Aldrich). These doses were based on previous psychopharmacological studies and are within normal testing range (Akiyoshi et al., 1995; Gorzalka et al., 1998; Hofmann et al., 2002; Mikklesen et al., 2004). Separate cohorts of animals were used for the hormonal studies (n=5 per group) and the behavioural/ thermal (n=7 per group) studies. All experiments were performed under the ethical consent of the Animal Care Committee of the University of British Columbia and the Canadian Council on Animal Care. Behavioural and thermal testing procedures All behavioural and thermal testing began at the onset of the dark cycle and was performed by blind observers. Immediately prior to injection of saline, 8-OH-DPAT or DOI, and 30, 60 and 90 min postinjection, all subjects had their rectal temperature
3 Chronic cannabinoid treatment on 5-HT receptors 279 measured with a Yellow Springs Instrument Series 400 thermister thermometer model (Yellow Springs, OH, USA). For each rectal temperature reading, rats were held at the base of the tail and the probe was inserted 5.2 cm past the rectum into the colon for 6 8 s until a rectal temperature was maintained for 3 s. Animals administered saline or DOI were also monitored for behavioural stereotypies. Immediately following injection of DOI or saline, subjects were placed into a Plexiglas testing bin (60 cmr45 cmr 45 cm) lined with Aspen chip bedding. During a 30-min interval in the testing bin, they were scored for the occurrence of wet-dog shakes (defined as a paroxysmal shudder of the head, neck and trunk; Bedard and Pycock, 1977; Gorzalka and Hanson, 1998) and back muscle contractions (defined as a clear-cut powerful contraction sweeping from the back of the neck along the back to the tail; Fone et al., 1989). Plasma collection and radioimmunoassay Following 12 d administration of HU-210 or vehicle, animals were again divided into three subgroups: (1) 0.9% saline; (2) 0.3 mg/kg 8-OH-DPAT; (3) 1 mg/kg DOI. Twenty-four hours following the last HU-210 or vehicle injection, subjects were administered an injection of saline, 8-OH-DPAT or DOI at the onset of the dark cycle (when the circadian level of corticosterone is at its trough), and returned to their home cages. Thirty minutes following injection, subjects were removed from their home cage and rapidly decapitated and their trunk blood was collected. Upon collection of trunk blood, samples were stored overnight at 4 xc and centrifuged the following morning at rpm for 10 min. Serum was removed and centrifuged again at rpm for 10 min and stored in a freezer at x20 xc until analysis. Serum was assayed for corticosterone levels with a standard radioimmunoassay kit and all samples were run in duplicate (Diagnostic Systems Laboratories Inc., Webster, TX, USA). Specifically, samples were thawed and aliquoted into polystyrene test tubes containing rat corticosterone standard. Rat [ 125 I]corticosterone reagent was immediately added followed by rat corticosterone antiserum, after which all samples were vortexed briefly and left to incubate in a water bath at 37 xc for 60 min. Following incubation, all samples had 1 ml of precipitating agent added and were vortexed briefly and left to incubate at room temperature (25 xc) for 15 min. All tubes were then centrifuged for 15 min at 3000 rpm. All tubes were then decanted in a sponge rack and blotted to remove all fluid. Tubes were then quantified in a gamma counter at 1 min per tube. Statistical analysis Data for behavioural and hormonal measures were analysed using a univariate analysis of variance (ANOVA) with serotonergic drug (8-OH-DPAT or DOI) and cannabinoid treatment as fixed factors. Data for thermal measurements were analysed using a repeated-measures ANOVA with both serotonergic drug and cannabinoid treatment as fixed factors. Tukey s post-hoc test was performed on all data and significance levels were set at p<0.05. Results Chronic cannabinoid treatment on 5-HT 2A receptor-mediated responses There was a significant interaction between DOI and HU-210 treatment on the expression of DOI-induced wet-dog shakes [F(1, 24)=6.871, p<0.02], with significant main effects of both DOI [F(1, 24)=43.85, p< 0.001] and HU-210 treatment [F(1, 24)=10.51, p<0.01]. Post-hoc analysis demonstrated that DOI significantly increased wet-dog-shake expression compared to control treatment (p<0.05), and that chronic pretreatment with HU-210 significantly potentiated DOI-induced wet-dog shakes (p<0.01). Furthermore, chronic pretreatment with HU-210 alone did not alter basal (non-doi) wet-dog-shake levels (p=0.97). Data for the effect of chronic HU-210 pretreatment on DOI-induced wet-dog shakes can be seen in Figure 1a. There was also a significant interaction between DOI and HU-210 treatment on the expression of DOIinduced back muscle contractions [F(1, 24)=4.886, p<0.05], with significant main effects of both DOI [F(1, 24)=37.50, p<0.001] and HU-210 treatment [F(1, 24)=4.886, p<0.05]. Post-hoc analysis demonstrated that DOI significantly increased back muscle contractions relative to control animals (p<0.001), but chronic pretreatment with HU-210 significantly attenuated the magnitude of this effect (p<0.05 relative to DOI alone, but p>0.05 relative to the control group). Chronic HU-210 pretreatment alone did not affect basal levels of back muscle contractions (p=1.0). Data for the effect of chronic HU-210 pretreatment on DOI-induced back muscle contractions can be seen in Figure 1b. The effect of HU-210 pretreatment on DOI-induced hyperthermia could not be assessed in this experiment as animals that had been pretreated with HU-210 and were administered DOI exhibited pronounced signs of a 5-HT syndrome that was specifically characterized by a severe hyperthermia (core temperatures exceeded 43 xc in most subjects). By the 60-min timepoint (third temperature measurement), over half of
4 280 M. N. Hill et al. (a) 30 Wet-dog shakes (b) 30 Back muscle contractions * Control these animals had unexpectedly died. Despite insufficient data for a repeated-measures analysis, these findings suggest that the hyperthermic response to DOI was potentiated by chronic HU-210 pretreatment. There was, however, no significant interaction between DOI and HU-210 treatment on DOI-induced increases in corticosterone secretion [F(1, 16)=0.082, p>0.05]; however, there was a significant main effect of DOI [F(1, 16)=99.65, p<0.001], but no significant main effect of HU-210 treatment [F(1, 16)=0.052, p>0.05]. Data for the effect of chronic HU-210 pretreatment on DOI-induced changes in corticosterone secretion can be seen in Figure 2. Chronic cannabinoid treatment on 5-HT 1A receptor-mediated hypothermia There was a significant interaction between time, 8-OH-DPAT and HU-210 treatment on the 8-OH- * * * Control Figure 1. The effect of 12 d administration of the potent cannabinoid CB receptor agonist HU-210 (100 mg/kg. d) on DOI-induced: (a) wet-dog shakes; (b) back muscle contractions. Values are denoted as means S.E.M. of total behavioural frequency in a 30-min testing period. * Denotes significant differences between identified groups (p<0.05) (n=7 per group). %, Control; &, DOI. Corticosterone (ng/ml) * Control DPAT-mediated hypothermic response [F(2, 48)=3.17, p<0.05]. Furthermore, there was also a significant interaction between time and 8-OH-DPAT [F(2, 48) =4.45, p<0.05], but not a significant interaction between time and HU-210 treatment [F(2, 48)=1.02, p>0.05]. Post-hoc analysis demonstrated that 8-OH- DPAT treatment significantly reduced core temperature between time 0 and time 30 (p<0.01). Animals that had been pretreated with HU-210 and received a challenge dose of 8-OH-DPAT did not differ in temperature changes from control animals (p=0.41), and exhibited significantly less hypothermia than vehicle-pretreated animals also administered 8-OH- DPAT (p<0.001). At 60-min post-injection, the hypothermic effect of the 8-OH-DPAT challenge in vehicle-pretreated animals continued to be significantly lower than vehicle-pretreated animals that received a vehicle challenge (p<0.01). At the 60-min time-point, animals which had been pretreated with chronic HU-210 and administered an 8-OH-DPAT challenge exhibited no significant change in core temperature relative to vehicle-vehicle-treated animals (p=0.98) and exhibited significantly less hypothermia than vehicle-pretreated 8-OH-DPAT-administered animals (p<0.02). However, HU-210 pretreatment followed by a vehicle challenge did result in a very small, but significant, elevation in core temperature at 60 min (p<0.05). At 90 min, there was a non-significant trend towards a reduction in core temperature with 8-OH-DPAT administration in vehicle-pretreated animals (p<0.09). Although HU- 210 pretreatment followed by a vehicle challenge had no effect on core temperature at this time-point (p>0.05), HU-210 pretreated animals subsequently * Figure 2. The effect of 12 d administration of the potent cannabinoid CB receptor agonist HU-210 (100 mg/kg. d) on DOI-induced changes in serum corticosterone levels. Values are denoted as means S.E.M. of serum corticosterone levels (ng/ml). * Denotes significant differences between identified groups (p<0.05) (n=5 per group). %, Control ; &, DOI.
5 Chronic cannabinoid treatment on 5-HT receptors 281 Change in temperature from baseline ( C) Control 8-OH-DPAT + 8-OH-DPAT 30 given a 8-OH-DPAT challenge exhibited significantly less hypothermia than vehicle-pretreated animals given a 8-OH-DPAT challenge (p<0.01). Data indicating the time-course of the effect of chronic HU-210 pretreatment on the hypothermic effects of 8-OH-DPAT can be seen in Figure 3. There was a significant interaction between 8-OH- DPAT and HU-210 treatment on the 8-OH-DPATinduced increase in corticosterone secretion [F(1, 16)= 30.29, p<0.001], with significant main effects of both 8-OH-DPAT treatment [F(1, 16)=31.34, p<0.001] and HU-210 treatment [F(1, 16)=50.25, p<0.001]. Post-hoc analysis revealed that 8-OH-DPAT administration significantly increased serum corticosterone levels relative to control levels (p<0.001). However, following pretreatment with HU-210, 8-OH-DPAT administration failed to increase serum corticosterone levels relative to control levels (p=0.72). Furthermore, 8-OH-DPAT administration to HU-210 pretreated animals resulted in a significantly smaller change in serum corticosterone than 8-OH-DPAT administration to vehicle-treated animals (p<0.001). treatment alone had no effect on serum corticosterone Time (min) Figure 3. The effect of 12 d administration of the potent cannabinoid CB receptor agonist HU-210 (100 mg/kg. d) on 8-OH-DPAT-induced hypothermia. Values are denoted as means S.E.M. temperature (xc) differences from time 0. * Denotes a significant difference between 8-OH-DPAT and 8-OH-DPAT/chronic HU-210 treatment; $ denotes a significant difference between either 8-OH-DPAT or chronic HU-210 and control; for both significant differences, p<0.05 (n=7 per group). Corticosterone (ng/ml) levels (p=0.68). Data indicating the effect of chronic HU-210 pretreatment on the adrenocortical response to 8-OH-DPAT administration can be seen in Figure 4. Discussion * * Control Figure 4. The effect of 12 d administration of the potent cannabinoid CB receptor agonist HU-210 (100 mg/kg. d) on 8-OH-DPAT-induced changes in serum corticosterone levels. Values are denoted as means S.E.M. of serum corticosterone levels (ng/ml). * Denotes significant differences between identified groups (p<0.05) (n=5 per group). %, Control; &, 8-OH-DPAT. This research demonstrated that prolonged treatment with the potent cannabinoid CB receptor agonist HU- 210 resulted in an apparent dysregulation of 5-HT receptor subtypes. Behaviourally, chronic cannabinoid treatment potentiated 5-HT 2A receptor-mediated wetdog shakes, but decreased back muscle contractions. Furthermore, in animals that had been pretreated with chronic HU-210, a standard 1 mg/kg dose of DOI resulted in a sudden and unanticipated mortality in four of the seven subjects within 60 min from an apparent serotonin syndrome. By contrast, neither this dose of DOI in vehicle-treated animals, nor HU-210 treatment alone had an effect on mortality rates. While we could not examine the time-course of the hyperthermic effect of DOI (due to a loss of subjects), body temperatures exceeded 43 xc in subjects that subsequently died, suggesting that hyperthermia from DOI was enhanced following HU-210 treatment. Interestingly, the adrenocortical response elicited by DOI was unchanged following chronic HU-210 administration, suggesting that cannabinoid-induced changes in 5-HT 2A receptor activity may be region specific. However, the possibility also exists that the adrenocortical response from DOI had reached a ceiling effect in the vehiclepretreated animals and thus, we were unable to detect an increase beyond that value. The ability of DOI to induce wet-dog shakes has been linked to several neuroanatomical regions, such
6 282 M. N. Hill et al. as the nucleus raphe obscurus/inferior olive (Watson and Gorzalka, 1992), spinal cord (Fone et al., 1991) and the medial prefrontal cortex (Willins and Meltzer, 1997). While it has been demonstrated that wet-dog shakes induced by the 5-HT precursor, 5-HTP, remain intact following ablation of the frontal cortex (Lucki and minugh-purvis, 1987), this alone does not demonstrate that changes in cortical levels of 5-HT 2A receptors would not be capable of modulating DOI-induced wet-dog shakes. Both chronic stress and glucocorticoid treatment enhance DOI-induced wetdog shakes (Gorzalka and Hanson, 1998; Takao et al., 1997), but appear to exclusively up-regulate 5-HT 2A receptors in the cortex (Fernandes et al., 1997; Kuroda et al., 1992). Alternatively, chronic antidepressant administration selectively down-regulates 5-HT 2A receptors in the cortex while concurrently reducing DOI-induced wet-dog shakes (Goodwin et al., 1984; Metz and Heal, 1986). This suggests a strong correlation between cortical 5-HT 2A receptors and wet-dog shakes (Willins and Meltzer, 1997), and the possibility that chronic cannabinoid treatment may up-regulate 5-HT 2A receptors in the cortex. The hypothesis that this enhancement of DOI-induced wet-dog shakes may be due to up-regulation of 5-HT 2A receptors in the frontal cortex, rather than in the spine is supported by the evidence that DOI-induced back muscle contractions, which are mediated by spinal 5-HT 2A receptors (Fone et al., 1991), are down-regulated by chronic treatment with HU-210. Additionally, the adrenocortical response to DOI was unchanged, which suggests that hypothalamic 5-HT 2A receptors remain unchanged following this treatment; however, this cannot explain the apparent changes seen in hyperthermia. Ultimately, quantitative autoradiography would have to be performed to gain an exact understanding of the region-specific (and possibly hypothalamic nuclei-specific) changes in 5-HT 2A receptor levels following chronic cannabinoid treatment. The hypothermic response to administration of the 5-HT 1A receptor agonist 8-OH-DPAT was significantly attenuated at all time-points measured (30-, 60- and 90-min post-injection) in animals that had been pretreated with chronic HU-210. Moreover, the adrenocortical response elicited by 8-OH-DPAT was completely attenuated following chronic HU-210 treatment. These two parameters have been proposed to represent activation of somatodendritic 5-HT 1A receptors in the dorsal raphe which regulate 5-HT neuronal firing and post-synaptic 5-HT 1A receptors in limbic regions such as the hippocampus and hypothalamus respectively (Lesch, 1991). Thus, these data suggest that prolonged cannabinoid administration results in a decrease in both pre- and post-synaptic 5-HT 1A receptor activity. This could reflect a general down-regulation of the 5-HT 1A receptor throughout the brain, or it could represent a decrement in the signalling cascade initiated by the 5-HT 1A receptor, possibly due to alterations in G-protein subunit expression or coupling capacity. The exact nature of this desensitization requires further investigation. This imbalance of 5-HT receptor responsiveness is reminiscent of changes that are seen following chronic stress or glucocorticoid administration (Bagdy et al., 1989; Berendsen et al., 1996; Gorzalka and Hanson, 1998; Gorzalka et al., 1998; Takao et al., 1997). Glucocorticoids may be one of several mediating factors in the cannabinoidergic modulation of 5-HT receptor balance, as administration of CB 1 receptor agonists at doses comparable to those used in this study, elicit a robust adrenocortical response (Rodriguez de Fonseca et al., 1996, 1997). There is controversy over whether tolerance develops to this effect as some research has shown that corticosterone levels are not necessarily elevated following successive administration of a CB 1 receptor agonist (Pertwee, 1974); however, several studies have also demonstrated that even after multiple administrations, CB 1 receptor agonists do elicit a significant elevation in glucocorticoids (Collu, 1976; Miczek and Dixit, 1980; Wirguin et al., 1994). The data from this study demonstrate that basal corticosterone levels are not altered following long-term cannabinoid treatment; however, we did not assess if corticosterone levels increased immediately following the last HU-210 injection. In any event it is unlikely that corticosterone is the only factor mediating the changes documented in this study. While long-term glucocorticoid treatment sensitizes DOI-induced wet-dog shakes and desensitizes 8-OH-DPAT-mediated hypothermia, no changes in the lethality of DOI have ever been documented following this treatment (Gorzalka and Hanson, 1998; Gorzalka et al., 1998; Matuszewich and Yamamoto, 2003; Takao et al., 1997). However, it should be noted that 10-d treatment with corticosterone has been documented to enhance the induction of 5-HT syndrome in response to carbidopa and 5-hydroxytryptophan, demonstrating that glucocorticoids do possess the ability to sensitize the induction of 5-HT syndrome (Young et al., 1992). Ultimately, the possibility exists that in addition to altering either receptor level or sensitivity, prolonged cannabinoid treatment probably modifies other parameters of the 5- HT system. For example, if levels of 5-HT transporter were down-regulated by chronic cannabinoid treatment, this would result in a basal elevation of synaptic
7 Chronic cannabinoid treatment on 5-HT receptors HT levels, which in conjunction with DOI administration, could lead to the fatal serotonin syndrome documented here. This hypothesis requires further investigation. Alternatively, prolonged cannabinoid treatment may alter tryptophan hydroxylase activity or monoamine oxidase activity, or other enzymes involved in the synthesis or metabolism of 5-HT. However, given that CB 1 receptors themselves are located in brain regions implicated in thermoregulation, adrencortical activation and serotonin syndrome, such as the hypothalamus, cortex and raphe nuclei (Herkenham et al., 1991), the possibility also exists that any changes in 5-HT receptor expression or activity could be due to direct actions of the CB 1 receptor. Due to the reciprocal nature of these receptors, one cannot rule out the possibility that changes in 5-HT 2A receptor activity drove changes in 5-HT 1 A receptor activity, or vice versa. This is supported by evidence that 5-HT 1A receptors exert negative regulation over 5-HT 2A receptors (Ashby et al., 1994; Darmani et al., 1990; Willins and Meltzer, 1997). Thus, long-term cannabinoid treatment might result in a shift in the balance of 5-HT receptor activity, such that a net enhancement of 5-HT 2A receptor-mediated activity predominates, perhaps via a decrement in 5-HT 1A receptor activity. Clinically, these findings may have relevance as depression is often thought of as a disorder of the 5-HT system. While there is no conclusive evidence that 5-HT levels per se are disturbed in depression, several studies suggest that 5-HT 2A receptors are upregulated and 5-HT 1A receptors are down-regulated in depression and suicide (Bhagwagar et al., 2004; Drevets et al., 1999; Hrdina et al., 1993; Mann et al., 1989; Sargent et al., 2000). Moreover, there is a growing body of clinical evidence suggesting that long-term cannabis use may be associated with the development of depressive symptoms and suicide (Bovasso, 2001; Degenhardt et al., 2003; Lynskey et al., 2004). Our data provide a potential neurochemical explanation for the association between long-term cannabis use and the induction of depression. The data presented here demonstrate that long-term administration of the potent cannabinoid HU-210 results in an apparent up-regulation of 5-HT 2A receptor activity and a down-regulation of 5-HT 1A receptor activity. Furthermore, the blunted adrenocortical and hypothermic response to administration of 8-OH- DPAT found following long-term cannabinoid treatment in this study are very reminiscent of the attenuated hormonal and hypothermic responses to 5-HT 1A receptor agonists in depressed individuals (Cowen et al., 1994; Lesch et al., 1990a c; Meltzer and Maes, 1995; Shapira et al., 2000). These are the first data to demonstrate that chronic cannabinoid treatment can modify the 5-HT system and may aid in understanding the effects long-term cannabis use has on affective behaviour and disease. Acknowledgements This research was supported by an operating grant to B.B.G. from the Natural Sciences and Engineering Research Council of Canada (NSERC) and a postgraduate NSERC scholarship and a postgraduate trainee award from the Michael Smith Foundation for Health Research to M.N.H. Statement of Interest None. References Abdel-Fattah AF, Matsumoto K, el-hady KA, Watanabe H (1995). 5-HT1A and 5-HT2 receptors mediate hypo- and hyperthermic effects of tryptophan in pargyline-pretreated rats. Pharmacology Biochemistry and Behavior 52, Abrams JK, Johnson PL, Hollis JH, Lowry CA (2004). Anatomic and functional topography of the dorsal raphe nucleus. Annals of the New York Academy of Science 1018, Akiyoshi J, Tsuchiyama K, Yamada K, Oba A, Yamada K, Kojima K, Sasaki I, Nagayama H (1995). Effects of 8-OH- DPAT on corticosterone after acute and chronic administration of antidepressants. Progress in Neuropsychopharmacology and Biological Psychiatry 19, Araneda R, Andrade R (1991). 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in the rat association cortex. Neuroscience 40, Ashby CR, Edwards E, Wang RY (1994). Electrophysiological evidence for a functional interaction between 5-HT 1A and 5-HT 2A receptors in the rat medial prefrontal cortex: an ionophoretic study. Synapse 17, Backus LI, Sharp T, Grahame-Smith DG (1990). Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. British Journal of Pharmacology 100, Bagdy G, Calogero AE, Aulakh CS, Szemeredi K, Murphy DL (1989). Long-term cortisol treatment impairs behavioral and neuroendocrine responses to 5-HT 1 agonists in the rat. Neuroendocrinology 50, Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38, Bedard P, Pycock CJ (1977). Wet-dog shake behaviour in the rat: a possible quantitative model of central
8 284 M. N. Hill et al. 5-hydroxytryptamine activity. Neuropharmacology 16, Berendsen HH, Kester RC, Peeters BW, Broekkamp CL (1996). Modulation of 5-HT receptor subtype-mediated behaviours by corticosterone. European Journal of Pharmacology 308, Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ (2004). Persistent reduction in brain serotonin1a receptor binding in recovered depressed men measured by positron emission tomography with [ 11 C]WAY Molecular Psychiatry 9, Bobker DH (1994). A slow excitatory postsynaptic potential mediated by 5-HT2 receptors in nucleus prepositus hypoglossi. Journal of Neuroscience 14, Boger DL, Patterson JE, Jin Q (1998). Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide. Proceedings of the National Academy of Sciences USA 95, Bovasso GB (2001). Cannabis abuse as a risk factor for depressive symptoms. American Journal of Psychiatry 158, Chaperon F, Thiebot MH (1999). Behavioral effects of cannabinoid agents in animals. Critical Reviews in Neurobiology 13, Cheer JF, Cadogan AK, Marsden CA, Fone KC, Kendall DA (1999). Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38, Collu R (1976). Endocrine effects of chronic intraventricular administration of delta9-tetrahydrocannabinol to prepuberal and adult male rats. Life Sciences 18, Cowen PJ, Power AC, Ware CJ, Anderson IM (1994). 5-HT 1A receptor sensitivity in major depression: A neuroendocrine study with buspirone. British Journal of Psychiatry 164, Craven RM, Grahame-Smith DG, Newberry NR (2001). 5-HT1A and 5-HT2 receptors differentially regulate the excitability of 5-HT-containing neurones of the guinea pig dorsal raphe nucleus in vitro. Brain Research 899, Darmani NA (2001). Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Pharmacology, Biochemistry and Behavior 68, Darmani NA, Janoyan JJ, Kumar N, Crim JL (2003). Behaviorally active doses of the CB1 receptor antagonist SR A increase brain serotonin and dopamine levels and turnover. Pharmacology, Biochemistry and Behavior 75, Darmani NA, Martin BR, Pandey U, Glennon RA (1990). Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacology, Biochemistry and Behavior 36, Darmani NA, Martin BR, Pandey U, Glennon RA (1991). Inhibition of 5-HT2 receptor-mediated head-twitch response by cocaine via indirect stimulation of adrenergic alpha 2 and serotonergic 5-HT1A receptors. Pharmacology, Biochemistry and Behavior 38, Degenhardt L, Hall W, Lynskey M (2003). Exploring the association between cannabis use and depression. Addiction 98, Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier C, Mathis C (1999). PET imaging of serotonin 1A receptor binding in depression. Biological Psychiatry 46, Egashira N, Mishima K, Katsurabayashi S, Yoshitake T, Matsumoto Y, Ishida J, Yamaguchi M, Iwasaki K, Fujiwara M (2002). Involvement of 5-hydroxytryptamine neuronal system in Delta(9)-tetrahydrocannabinolinduced impairment of spatial memory. European Journal of Pharmacology 445, Eison AS, Eison MS (1994). Serotonergic mechanisms in anxiety. Progress in Neuropsychopharmacology and Biological Psychiatry 18, Fernandes C, McKittrick CR, File SE, McEwen BS (1997). Decreased 5-HT1A and increased 5-HT2A receptor binding after chronic corticosterone associated with a behavioural indication of depression but not anxiety. Psychoneuroendocrinology 22, Fone KC, Johnson JV, Bennett GW, Marsden CA (1989). Involvement of 5-HT2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CG 3509) to rats. British Journal of Pharmacology 96, Fone KC, Robinson AJ, Marsden CA (1991). Characterization of the 5-HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5-HT agonists in rats. British Journal of Pharmacology 103, Goodwin GM, Green AR, Johnson P (1984). 5-HT2 receptor characteristics in frontal cortex and 5-HT2 receptormediated head-twitch behaviour following antidepressant treatment to mice. British Journal of Pharmacology 83, Gorzalka BB, Hanson LA (1998). Sexual behavior and wet dog shakes in the male rat: regulation by corticosterone. Behavioral Brain Research 97, Gorzalka BB, Hanson LA, Brotto LA (1998). Chronic stress effects on sexual behavior in male and female rats : mediation by 5-HT2A receptors. Pharmacology, Biochemistry and Behavior 61, Gorzalka BB, Hill MN, Sun JC (2005). Functional role of the endocannabinoid system and AMPA/Kainate receptors in 5-HT 2A receptor-mediated wet dog shakes. European Journal of Pharmacology. doi: /j.ejphar Gorzalka BB, Mendelson SD, Watson NV (1990). Serotonin receptor subtypes and sexual behavior. Annals of the New York Academy of Sciences 600, Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience 11, Hofmann CE, Simms W, Yu WK, Weinberg J (2002). Prenatal ethanol exposure in rats alters serotonergic-mediated behavioral and physiological function. Psychopharmacology 161,
9 Chronic cannabinoid treatment on 5-HT receptors 285 Hrdina PD, Demeter E, Vu TB, Sotonyi P, Palkovits M (1993). 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Research 614, Kuroda Y, Mikuni M, Ogawa T, Takahashi K (1992). Effect of ACTH, adrenalectomy and the combination treatment on the density of 5-HT2 receptor binding sites in neocortex of rat forebrain and 5-HT2 receptor-mediated wet-dog shake behaviors. Psychopharmacology 108, Lesch KP (1991). 5-HT 1A receptor responsivity in anxiety disorders and depression. Progress in Neuropsychopharmacology and Biological Psychiatry 15, Lesch KP, Disselkamp-Tietze J, Shmidtke A (1990a). 5-HT 1A receptor function in depression: Effect of chronic amitriptyline treatment. Journal of Neural Transmission 80, Lesch KP, Mayer S, Disselkamp-Tietze J, Hoh A, Schoellnhammer G, Schulte HM (1990b). Subsensitivity of the 5-hydroxytryptamine 1A (5-HT 1A ) receptor-mediated hypothermic response to ipsapirone in unipolar depression. Life Sciences 46, Lesch KP, Mayer S, Disselkamp-Tietze J, Hoh A, Wiesmann M, Osterheider M, Schulte HM (1990c). 5-HT 1A receptor responsivity in depression: evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biological Psychiatry 28, Lucki I, Minugh-Purvis N (1987). Serotonin-induced head shaking behavior in rats does not involve receptors located in the frontal cortex. Brain Research 420, Lynskey MT, Glowinski AL, Todorov AA, Bucholz KK, Madden PA, Nelson EC, Statham DJ, Martin NG, Heath AC (2004). Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Archives of General Psychiatry 61, Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ (1989). Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. British Journal of Psychiatry (Suppl.) 8, Matuszewich L, Yamamoto BK (2003). Long-lasting effects of chronic stress on DOI-induced hyperthermia in male rats. Psychopharmacology 169, Meltzer HY, Maes M (1995). Effects of ipsapirone on plasma cortisol and body temperature in major depression. Biological Psychiatry 38, Metz A, Heal DJ (1986). In mice repeated administration of electroconvulsive shock or desmethylimipramine produces rapid alterations in 5-HT2-mediated head-twitch responses and cortical 5-HT2 receptor number. European Journal of Pharmacology 126, Miczek KA, Dixit BN (1980). Behavioral and biochemical effects of chronic delta 9-tetrahydrocannabinol in rats. Psychopharmacology 67, Mikkelsen JD, Hay-Schmidt A, Kiss A (2004). Serotonergic stimulation of the rat hypothalamo-pituitary-adrenal axis: interaction between 5-HT1A and 5-HT2A receptors. Annals of the New York Academy of Sciences 1018, Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E (2000). Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Archives of Pharmacology 361, Pertwee RG (1974). Tolerance to the effect of delta1- tetrahydrocannabinol on corticosterone levels in mouse plasma produced by repeated administration of cannabis extract or delta1-tetrahydrocannabinol. British Journal of Pharmacology 51, Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F (1997). Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276, Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, Navarro M (1996). Corticotropinreleasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. Journal of Pharmacology and Experimental Therapeutics 276, Santucci V, Storme JJ, Soubrie P, Le Fur G (1996). Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sciences 58, PL103 PL110. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ (2000). Brain serotonin1a receptor binding measured by positron emission tomography with [ 11 C]WAY : effects of depression and antidepressant treatment. Archives of General Psychiatry 57, Shapira B, Newman ME, Gelfin Y, Lerer B (2000). Blunted temperature and cortisol responses to ipsapirone in major depression: lack of enhancement by electroconvulsive therapy. Psychoneuroendocrinology 25, Simansky KJ (1996). Serotonergic control of the organization of feeding and satiety. Behavioral Brain Research 73, Takao K, Nagatani T, Kitamura Y, Yamawaki S (1997). Effects of corticosterone on 5-HT1A and 5-HT2 receptor binding and on the receptor-mediated behavioral responses of rats. European Journal of Pharmacology 333, Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG (2003). The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology 138, Watson NV, Gorzalka BB (1992). Concurrent wet dog shaking and inhibition of male rat copulation after ventromedial brainstem injection of the 5-HT2 agonist DOI. Neuroscience Letters 141, Willins DL, Meltzer HY (1997). Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. Journal of Pharmacology and Experimental Therapeutics 282,
10 286 M. N. Hill et al. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T (1994). Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28, Young AH, MacDonald LM, St John H, Dick H, Goodwin GM (1992). The effects of corticosterone on 5-HT receptor function in rodents. Neuropharmacology 31,
Drugs, The Brain, and Behavior
Drugs, The Brain, and Behavior John Nyby Department of Biological Sciences Lehigh University What is a drug? Difficult to define Know it when you see it Neuroactive vs Non-Neuroactive drugs Two major categories
More informationNeurobiology of Depression in Relation to ECT. PJ Cowen Department of Psychiatry, University of Oxford
Neurobiology of Depression in Relation to ECT PJ Cowen Department of Psychiatry, University of Oxford Causes of Depression Genetic Childhood experience Life Events (particularly losses) Life Difficulties
More informationNeuroscience An extra bit. Dr Sasha Gartside Institute of Neuroscience Newcastle University
Neuroscience An extra bit Dr Sasha Gartside Institute of Neuroscience Newcastle University Drugs, receptors, and transporters Most psychoactive drugs interfere with neurotransmission The main targets are
More informationIntroduction to Tolerance, Physical Dependence and Withdrawal
Introduction to Tolerance, Physical Dependence and Withdrawal Carrie G Markgraf, MD, PhD Safety Assessment Merck Research Laboratories 1 Overview Definitions Addiction, psychological dependence, physical
More informationBrain Damage & Recovery: The Resilience of the Brain, Addiction Impact & Therapeutic Repair. Michael Fishman, MD Director of Young Adult Program
Brain Damage & Recovery: The Resilience of the Brain, Addiction Impact & Therapeutic Repair Michael Fishman, MD Director of Young Adult Program How Addiction Takes Hold Large & rapid upsurges in dopamine
More informationSlide 1: Introduction Introduce the purpose of your presentation. Indicate that you will explain how the brain basically works and how and where
Slide 1: Introduction Introduce the purpose of your presentation. Indicate that you will explain how the brain basically works and how and where drugs such as heroin and cocaine work in the brain. Tell
More informationAMPHETAMINE AND COCAINE MECHANISMS AND HAZARDS
AMPHETAMINE AND COCAINE MECHANISMS AND HAZARDS BARRY J. EVERITT Department of Experimental Psychology, University of Cambridge Stimulant drugs, such as cocaine and amphetamine, interact directly with dopamine
More informationInfluence of positive allosteric modulation of the mglu2-receptor on the behavioral responses in animal models of depression
Influence of positive allosteric modulation of the mglu2-receptor on the behavioral responses in animal models of depression Neuroscience Discovery Janssen Research and Development, a Division of Janssen
More informationCauses of Alcohol Abuse and Alcoholism: Biological/Biochemical Perspectives
Causes of Alcohol Abuse and Alcoholism: Biological/Biochemical Perspectives Neurobehavioral Aspects of Alcohol Consumption Source: Eighth Special Report to the U.S. Congress on Alcohol and Health Secretary
More informationTreatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
More informationTolerance and Dependence
Tolerance and Dependence Drug Tolerance is a decrease in the effect of a drug as a consequence of repeated exposure. Change over repeated exposures. Different effects may show different tolerance. Tolerance
More informationDiseases of the Nervous System. Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University
Diseases of the Nervous System Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University Outline A. Stress-related Disorders 1. Emotional Circuitry: Key Components 2. The Hypothalamic
More informationWHAT HAPPENS TO OUR BRAIN?
WORK DYNAMIC The final result of this session is the formulation of the questions that, within the activity of the Let s talk about drugs programme of the la Caixa Welfare Project, you will ask Dr. Rafael
More informationBehavioral Neuroscience (BCPSY 1117, 1119) Course Syllabus
Instructor: E mett McCaskill, Ph.D. Email: emccaski@barnard.edu Phone: 212-854-8601 Course Description Behavioral Neuroscience (BCPSY 1117, 1119) Course Syllabus Behavioral Neuroscience is the discipline
More informationAlcohol Withdrawal Syndrome & CIWA Assessment
Alcohol Withdrawal Syndrome & CIWA Assessment Alcohol Withdrawal Syndrome is a set of symptoms that can occur when an individual reduces or stops alcoholic consumption after long periods of use. Prolonged
More information1. According to recent US national estimates, which of the following substances is associated
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
More informationANIMATED NEUROSCIENCE
ANIMATED NEUROSCIENCE and the Action of Nicotine, Cocaine, and Marijuana in the Brain Te a c h e r s G u i d e Films for the Humanities & Sciences Background Information This program, made entirely of
More informationVictims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years
Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957
More informationM.S., Psychology, 2005 Thesis title: Effects of neonatal novelty exposure on competitive ability and taskdirected
KATHERINE GOOLD AKERS Hospital for Sick Children Neurosciences and Mental Health 555 University Avenue Toronto, ON M5G 1X8 416-813-6898 katherine.akers@sickkids.ca CURRENT POSITION Hospital for Sick Children
More informationCHAPTER- 6. Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats. 1. Introduction. 2. Methods
CHAPTER- 6 Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats 1. Introduction Neurodegenerative disorders, such as AD are often characterized by the degeneration of the
More informationASSESSMENT ON THE EFFICACY OF SKUDO IN ELIMINATING ECTOPARASITES AND ON ITS EFFECTS ON DOGS HEALTH. Investigator: Prof. Dr. Gisele Zoccal Mingoti Veterinary Medicine State University Paolista (Unesp) Araçatuba
More informationEndocrine Responses to Resistance Exercise
chapter 3 Endocrine Responses to Resistance Exercise Chapter Objectives Understand basic concepts of endocrinology. Explain the physiological roles of anabolic hormones. Describe hormonal responses to
More informationIdentification, treatment and support for individuals with Alcohol & Drug Addiction in the Community
Identification, treatment and support for individuals with Alcohol & Drug Addiction in the Community Dr David Jackson Clinic Medical Officer The Hobart Clinic Association Drugs In tonight s context, drugs
More informationNEURON AND NEURAL TRAMSMISSION: ANATOMY OF A NEURON. created by Dr. Joanne Hsu
NEURON AND NEURAL TRAMSMISSION: ANATOMY OF A NEURON NEURON AND NEURAL TRAMSMISSION: MICROSCOPIC VIEW OF NEURONS A photograph taken through a light microscope (500x) of neurons in the spinal cord. NEURON
More informationsubstance abuse and addiction are complex phenomena
Executive Summary 1 substance abuse and addiction are complex phenomena that defy simple explanation or description. A tangled interaction of factors contributes to an individual s seeking out, using,
More informationSeminar/Talk Calendar
Seminar/Talk Calendar Tuesday, February 3rd Dr. John Neumaier, Professor of Psychiatry and Pharmacology, University of Washington DREADDing Addiction Dr. Neumaier s laboratory is studying stress and addiction
More informationTreating Mental Disorders. Types of Biological Treatment. Drug Treatments for Psychological Disorders
Treating Mental Disorders Biological Treatments for Psychological Disorders Aims: Describe and Assess Biological Treatments Objectives By the end of this session you should be able to: Describe the use
More informationFUNCTIONAL EEG ANALYZE IN AUTISM. Dr. Plamen Dimitrov
FUNCTIONAL EEG ANALYZE IN AUTISM Dr. Plamen Dimitrov Preamble Autism or Autistic Spectrum Disorders (ASD) is a mental developmental disorder, manifested in the early childhood and is characterized by qualitative
More informationRecognizing and Treating Depression in Children and Adolescents.
Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital
More informationASSIGNMENTS AND GRADING
Instructor: Janet Menard Office: Craine- 431 Phone: 533-3099 Email: menard@queensu.ca Class Hours: Tuesdays 11:30 1:00 Friday 1:00 2:30 Office Hours: Mondays 1:00-2:00 Thursdays 3:30-4:30 (please notify
More informationPTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program
Journal of Psychoactive Drugs, 46(1),73 77,2014 Copyright Taylor & Francis Group, LLC ISSN: 0279-1072 print / 2159-9777 online DOI: 10.1080/02791072.2013.873843 PTSD Symptom Reports of Patients Evaluated
More informationHow To Understand The Effects Of Drugs On The Brain
DRUGS AND THE BRAIN Most of the psychological and behavioural effects of psychoactive drugs is due the interaction they have with the nerve cells in the CNS (which includes the brain and peripheral nervous
More informationAcupuncture in Back Pain Management. Victoria Chan Harrison M.D. Assistant Professor of Rehabilitation Medicine Weill Cornell Medical College
Acupuncture in Back Pain Management Victoria Chan Harrison M.D. Assistant Professor of Rehabilitation Medicine Weill Cornell Medical College Objective Review the roots of acupuncture theory and basic Traditional
More informationNEUROPHARMACOLOGY AND ADDICTION CHRISTOPHER M. JONES, PHARMD, MPH
NEUROPHARMACOLOGY AND ADDICTION CHRISTOPHER M. JONES, PHARMD, MPH Disclosures This presentation does not represent the views of the US Public Health Service or the US Food and Drug Administration The majority
More informationMonoamine Oxidase in Major Depressive Disorder
Handout for the Neuroscience Education Institute (NEI) online activity: Monoamine Oxidase in Major Depressive Disorder Learning Objective Explain the role of monoamine oxidase in the neurobiology, etiology,
More informationAddiction Neurobiology
Addiction Neurobiology Stephen Jurd University of Sydney Australia Richard W is sick Apology The site of pathology IF Addiction has a neurobiological basis THEN we should be able to: Define addiction AND
More informationYamaguchi University, Japan
Yamaguchi University, Japan The United Graduate School of Veterinary Science The Stress Related Neuroendocrine and Metabolic Effects of Alpha-2 Adrenergic Agents and Their Combinations with Injectable
More informationThe Addicted Brain. And what you can do
The Addicted Brain And what you can do How does addiction happen? Addiction can happen as soon as someone uses a substance The brain releases a neurotransmitter called Dopamine into the system that makes
More informationSlide 4: Forebrain Structures. Slide 5: 4 Lobes of the Cerebral Cortex. Slide 6: The Cerebral Hemispheres (L & R)
Slide 1: [Film Clip: The Brain #2- Phineas Gage] Integrated Bodily Communications Within Brain (Hemispheres and structures) The remaining Nervous System Endocrine System (Hormonal communication) Our bodies-
More informationParoxetine for the treatment of depression in children and adolescents: A suicidal choice? By Laura Harding Supervisor Dr.
Paroxetine for the treatment of depression in children and adolescents: A suicidal choice? By Laura Harding Supervisor Dr. John Harris Frontispiece from the1638 edition of Robert Burton's The Anatomy of
More informationDrugs and Teens: Current Facts and Recent Trends. Agenda. Adolescent development
Drugs and Teens: Current Facts and Recent Trends Cheryl Houtekamer Youth Addiction Services Calgary Agenda Adolescent Development Brain Development Adolescent Substance Use - Prevalence How does addiction
More informationHow To Understand The Hypothalamus
883 Hypothalamus HYPOTHALAMUS Introduction The hypothalamus is a very small, but extremely important part of the diencephalon that is involved in the mediation of endocrine, autonomic and behavioral functions.
More informationGenetic and Other Risk Factors for Alcoholism and Alcohol Abuse. Manzardo, Ch 11,12 Fingarette, pp 51-55
Genetic and Other Risk Factors for Alcoholism and Alcohol Abuse Manzardo, Ch 11,12 Fingarette, pp 51-55 Suggestive Trends 80% of alcoholics in inpatient treatment have close relative with an alcohol problem
More informationHealth on the Homefront: PTSD, Its Clinical Description, Treatment and Underlying Pathophysiology
Health on the Homefront: Stephen I. Deutsch, M.D., Ph.D. Eastern Virginia Medical School World War I Shell Shock and Disordered Action of the Heart Tremors Tics Fatigue Memory loss Difficulty in sleeping
More informationWhy Meditation is successful in Substance abuse treatment. Mediation paired with substance abuse treatment has been around since 1982 when the
Stone Amber Stone Mathew Arndt HLTH-1240 26 June 2014 Why Meditation is successful in Substance abuse treatment. Mediation paired with substance abuse treatment has been around since 1982 when the Betty
More informationEPIDEMIC 4.6 % OF INDIVIDUALS 18 25 USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH.
Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF
More informationTITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines
TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 01 December 2009 CONTEXT AND POLICY ISSUES: Post-traumatic stress disorder
More informationName: Teacher: Olsen Hour:
Name: Teacher: Olsen Hour: The Nervous System: Part 1 Textbook p216-225 41 In all exercises, quizzes and tests in this class, always answer in your own words. That is the only way that you can show that
More information12 Steps to Changing Neuropathways. Julie Denton
12 Steps to Changing Neuropathways Julie Denton Review the neurobiology of the brain Understand the basics of neurological damage to the brain from addiction Understand how medications and psychotherapy
More information3. The neuron has many branch-like extensions called that receive input from other neurons. a. glia b. dendrites c. axons d.
Chapter Test 1. A cell that receives information and transmits it to other cells via an electrochemical process is called a(n) a. neuron b. hormone c. glia d. endorphin Answer: A difficulty: 1 factual
More informationEffects of Caffeine on Cardiac and Skeletal Muscle Stimulation: A Noninvasive Study Based on a Single Dose of Caffeine
Effects of Caffeine on Cardiac and Skeletal Muscle Stimulation: A Noninvasive Study Based on a Single Dose of Caffeine Physiology 435: Lab 601 Group 3 Dr. Lokuta Kira Arno, Logan Schlosser, Chris Boyd,
More informationUnderstanding Addiction: The Intersection of Biology and Psychology
Understanding Addiction: The Intersection of Biology and Psychology Robert Heimer, Ph.D. Yale University School of Public Health Center for Interdisciplinary Research on AIDS New Haven, CT, USA November
More informationPSK171 STRESS MANAGEMENT
PSK171 STRESS MANAGEMENT Chapter 2 Systems that control stress arousal Controlling Stress & Tension Girdano, Dusek & Everly Ligands Ligands (amino acid molecules) Biochemicals that carry information Neurohormones
More informationAlcohol and Brain Damage
Alcohol and Brain Damage By: James L. Holly, MD O God, that men should put an enemy in their mouths to steal away their brains! That we should, with joy, pleasance, revel, and applause, transform ourselves
More informationPHC 313 The 7 th. Lecture. Adrenergic Agents
PHC 313 The 7 th. Lecture Adrenergic Agents Introduction Introduction Adrenergic agents are a broad class of agents employed in the treatment of many disorders. They are those chemical agents that exert
More informationCURRICULUM VITAE. 223 Arroyo Grande Way Santa Clara University Los Gatos, CA 95032 Santa Clara, CA 95053 (408) 358-3092 (408) 554-4347
CURRICULUM VITAE Robert Numan Department of Psychology 223 Arroyo Grande Way Santa Clara University Los Gatos, CA 95032 Santa Clara, CA 95053 (408) 358-3092 (408) 554-4347 EDUCATION Ph.D. B.S. University
More informationChapter 7: The Nervous System
Chapter 7: The Nervous System Objectives Discuss the general organization of the nervous system Describe the structure & function of a nerve Draw and label the pathways involved in a withdraw reflex Define
More informationThe Brain, Behavior, and Addiction. Objectives. Advances in science have revolutionized our fundamental views of drug abuse and addiction.
The Brain, Behavior, and Addiction Flo Hilliard University of Wisconsin-Madison Division of Continuing Studies Objectives Progress of science in addiction studies Why it is a brain disease Changing our
More informationTreatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
More informationEFFECTS OF MDMA ON VIGILANCE AND PHARMACOLOGICAL CONSEQUENCES OF MDMA NEUROTOXICITY
SEMMELWEIS UNIVERSITY JÁNOS SZENTÁGOTHAI DOCTORAL SCHOOL OF NEUROSCIENCES Ph.D. thesis EFFECTS OF MDMA ON VIGILANCE AND PHARMACOLOGICAL CONSEQUENCES OF MDMA NEUROTOXICITY - Brigitta Balogh - Consultant:
More informationOverview. Unit 5: How do our choices change our brains?
Unit 5: How do our choices change our brains? Overview In the previous units, we learned about the neuron, synaptic transmission, and neuronal circuits. In this key culminating unit, we ll bring all of
More informationSubstance Addiction. A Chronic Brain Disease
Substance Addiction A Chronic Brain Disease What you will Learn Addiction is a Brain Disease Understand the Structure and Pathways Associated with changes in the brain. Addiction is a Chronic Condition
More informationNeurotrophic factors and Their receptors
Neurotrophic factors and Their receptors Huang Shu-Hong Institute of neurobiology 1 For decades, scientists believed that brain cells of the central nervous system could not regrow following damage due
More informationThe Neuron and the Synapse. The Neuron. Parts of the Neuron. Functions of the neuron:
The Neuron and the Synapse The Neuron Functions of the neuron: Transmit information from one point in the body to another. Process the information in various ways (that is, compute). The neuron has a specialized
More informationOVERVIEW OF MEDICATION ASSISTED TREATMENT
Sarah Akerman MD Assistant Professor of Psychiatry Director of Addiction Services Geisel School of Medicine/Dartmouth-Hitchcock Medical Center OVERVIEW OF MEDICATION ASSISTED TREATMENT Conflicts of Interest
More informationRegulation of Metabolism. By Dr. Carmen Rexach Physiology Mt San Antonio College
Regulation of Metabolism By Dr. Carmen Rexach Physiology Mt San Antonio College Energy Constant need in living cells Measured in kcal carbohydrates and proteins = 4kcal/g Fats = 9kcal/g Most diets are
More informationBeroendemekanismer- ett beroende som andra?
Beroendemekanismer- ett beroende som andra? Neuroendokrina responser till spel om pengar Anna Söderpalm Gordh Dopamine and the Rewardsystem Studies in animal models have demonstrated that mesocorticolimbic
More informationDepression in Older Persons
Depression in Older Persons How common is depression in later life? Depression affects more than 6.5 million of the 35 million Americans aged 65 or older. Most people in this stage of life with depression
More informationMultifamily Groups in the Treatment of Severe Psychiatric Disorders
Text from pages 7-12 of Multifamily Groups in the Treatment of Severe Psychiatric Disorders By William R. McFarlane (2002) ISBN 1-57230-743-9. Published by The guilford Press, 72 Spring Street, New York,
More informationHormones & Chemical Signaling
Hormones & Chemical Signaling Part 2 modulation of signal pathways and hormone classification & function How are these pathways controlled? Receptors are proteins! Subject to Specificity of binding Competition
More informationUNIVERSITY OF BOLTON EDUCATION & PSYCHOLOGY PSYCHOLOGY SEMESTER 1 EXAMINATIONS 2014/2015 COGNITIVE & BIOLOGICAL PERSPECTIVES MODULE NO: PSC4003
[EDP 005] UNIVERSITY OF BOLTON EDUCATION & PSYCHOLOGY PSYCHOLOGY SEMESTER 1 EXAMINATIONS 2014/2015 COGNITIVE & BIOLOGICAL PERSPECTIVES MODULE NO: PSC4003 Date: Wednesday 21 st January, 2015 Time: 2.00pm
More informationBSc in Medical Sciences with PHARMACOLOGY
BSc in Medical Sciences with PHARMACOLOGY Course Director Dr Christopher John Module Leaders Dr Robert Dickinson (Module 1) Dr Anabel Varela Carver (Module 2) Dr Sohag Saleh (Module 3) Course Administrator
More informationMechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochemistry Journal. August 1, 2007 405, pp.
Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies 1 Biochemistry Journal August 1, 2007 405, pp. 559 568 Joseph Friedman, Sarah Kraus, Yirmi Hauptman, Yoni Schiff
More informationActivation of CB1 Receptors May Provide an Effective Treatment for Obsessive Compulsive Disorder
Page 1 of 9 Activation of CB1 Receptors May Provide an Effective Treatment for Obsessive Compulsive Disorder Matthew Kirchner, Amy Jo Stavnezer College of Wooster, Wooster, Ohio 44691 Obsessive compulsive
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
More informationPrevention & Recovery Conference November 28, 29 & 30 Norman, Ok
Prevention & Recovery Conference November 28, 29 & 30 Norman, Ok What is Addiction? The American Society of Addiction Medicine (ASAM) released on August 15, 2011 their latest definition of addiction:
More informationPART I: Neurons and the Nerve Impulse
PART I: Neurons and the Nerve Impulse Identify each of the labeled structures of the neuron below. A. B. C. D. E. F. G. Identify each of the labeled structures of the neuron below. A. dendrites B. nucleus
More informationIntegration and Coordination of the Human Body. Nervous System
I. General Info Integration and Coordination of the Human Body A. Both the and system are responsible for maintaining 1. Homeostasis is the process by which organisms keep internal conditions despite changes
More informationThe latest in addiction medicine: What every nurse needs to know
CNA Webinar Series: Progress in Practice The latest in addiction medicine: What every nurse needs to know Monica Gregory Nurse Practitioner, Crosstown Clinic December 4, 2014 Canadian Nurses Association,
More informationChapter Fourteen. Emotion, Reward, Aggression, and Stress
Chapter Fourteen Emotion, Reward, Aggression, and Stress EMOTIONS! Emotions generally include a Physical component, and a Subjective component or quality, and a Valence Emotions a product of Evolution?
More informationCHAPTER 6 PRINCIPLES OF NEURAL CIRCUITS.
CHAPTER 6 PRINCIPLES OF NEURAL CIRCUITS. 6.1. CONNECTIONS AMONG NEURONS Neurons are interconnected with one another to form circuits, much as electronic components are wired together to form a functional
More informationNeuroscience Perspectives on Brain and Body Health. Importance of the Social Environment
{ Neuroscience Perspectives on Brain and Body Health Importance of the Social Environment Bruce S. McEwen, Ph.D. Alfred E. Mirsky Professor Head, Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology
More informationEffects of Two Proprietary Compounds in Multiple Sclerosis DATE
Effects of Two Proprietary Compounds in a Model of Multiple Sclerosis DATE Authentication This study was conducted under the terms of a Services Agreement between Inc. and CLIENT dated DATE. Sponsor XXX
More informationNEUROBIOLOGY OF CANNABIS ADDICTION Part I
NEURBILGY F CANNABIS ADDICTIN Part I 1. Definition and mechanism of action of cannabinoids 2. Addictive potential of cannabinoids and mechanisms involved 3. Cognitive effects of cannabinoids and mechanisms
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationNeuropharmacology II Antidepressants and Sedatives
Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Dr. David Standaert Standaert 1 Neuropharmacology II Antidepressants and Sedatives Depression A frequent
More informationIntroduction to Neurophysiological Psychology (PSY 451)
Portland State University Physiological Psychology Page 1 Introduction to Neurophysiological Psychology (PSY 451) Bill Griesar, Ph.D., Adjunct Instructor, bgriesar@pacifier.com OFFICE HOURS: Mondays, 11:30
More informationCAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological
More informationThe Limbic System Theory of Addiction
The Limbic System Theory of Addiction The brain controls every aspect of a human being. From breathing to blinking, it runs the show. Most of how it operates, however, is on an automatic and unconscious
More informationNeurophysiology. 2.1 Equilibrium Potential
2 Neurophysiology 2.1 Equilibrium Potential An understanding of the concepts of electrical and chemical forces that act on ions, electrochemical equilibrium, and equilibrium potential is a powerful tool
More informationRelationship Between Stress and Substance Use Disorders: Neurobiologic Interface
Relationship Between Stress and Substance Use Disorders: Neurobiologic Interface Kathleen Brady, M.D., Ph.D. Professor of Psychiatry Associate Dean of Clinical and Translational Research Medical University
More informationDependence and Addiction. Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania
Dependence and Addiction Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania Overview Heroin and other opiates The disease of heroin addiction or dependence Effective
More informationHeadache and Sleep Disorders 屏 東 基 督 教 醫 院 沈 秀 祝
Headache and Sleep Disorders 屏 東 基 督 教 醫 院 沈 秀 祝 Sleep Sleeping later Sleep deprivation Excessive Sleep Sleep Migraine Physiology of sleep Headache Clinical, Anatomical, and Physiologic Relationship Between
More informationDonald Stephen Leitner
Donald Stephen Leitner Department of Psychology Office: (610)660-1802 Saint Joseph s University Fax: (610)660-1819 5600 City Avenue e-mail: dleitner@sju.edu Philadelphia, PA 19131-1395 Laboratory: Post
More informationLESSON 5.7 WORKBOOK Is addiction a chronic disease?
DEFINITIONS OF TERMS Addiction is a disease idea that states drug addiction is no different from other chronic diseases, like diabetes and heart disease, and thus needs to be treated as a distinct medical
More informationObsessive Compulsive Disorder: a pharmacological treatment approach
Obsessive Compulsive Disorder: a pharmacological treatment approach Professor Alasdair Vance Head, Academic Child Psychiatry Department of Paediatrics University of Melbourne Royal Children s Hospital
More informationDipartimento di Neuroscienze, Università degli Studi di Torino e Istituto Nazionale di Neuroscienze (INN)
Dipartimento di Neuroscienze, Università degli Studi di Torino e Istituto Nazionale di Neuroscienze (INN) www.personalweb.unito.it / fabrizio.benedetti www.ist-nazionale-neuroscienze.unito.it Placebo Improvement
More informationOvertraining with Resistance Exercise
ACSM CURRENT COMMENT Overtraining with Resistance Exercise One of the fastest growing and most popular types of exercise in recent years is resistance exercise, whether used for the purpose of general
More informationAlcohol Overuse and Abuse
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
More informationJ. David Kinzie, M.D., FAC Psych. Professor of Psychiatry Oregon Health & Science University
J. David Kinzie, M.D., FAC Psych. Professor of Psychiatry Oregon Health & Science University 65-year-old Oromo male In the U.S. five years Interviewed the first time April, 2011 Symptoms: Almost no sleep,
More information